METASARC: Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa

Completed

• Conditions: Sarcoma; Metastases; Chemotherapy

• Registration Number: NCT03977818
• Lead Sponsor: Institut Bergonié

Brief Summary

Well-designed observational studies of individuals with rare tumors are needed to improve patient care, clinical investigations, and the education of healthcare professionals.

The patterns of care, outcomes, and prognostic factors of a cohort of 2225 patients with metastatic soft tissue sarcomas who were diagnosed between 1990 and 2013 and documented in the prospectively maintained database of the French Sarcoma Group will be analyzed with a focus on : number/frequency of systemic treatments per patient, number/frequency of patients with locoregional treatment of the metastasis, number/frequency of patients with chemotherapy, number/frequency of patients with an off-label drug.

Outcome (time-to-next treatment \[TNT\] and overall survival \[OS\]) will be reported according to histological subtype, as well as the association between TNT and OS.

Prognostic factors of OS will be investigated.

Detailed Description

Not available

Study Timeline

• Study Start: 1990-01-01
• Primary Completion: 2017-01-01
• Study Completion: 2017-01-01
• Study First Submitted: 2019-05-23
• Study First Submitted QC: 2019-06-05
• Study First Posted: 2019-06-06
• Results First Submitted: 2020-11-25
• Results First Submitted QC: 2020-11-25
• Status Verified: 2020-12
• Results First Posted: 2020-12-21
• Last Update Submitted: 2020-12-30
• Last Update Posted: 2021-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2165

Inclusion Criteria

• advanced soft tissue sarcoma
• age > 18

Read More

Exclusion Criteria

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment	2 years	TNT: time from the systemic treatment onset to the next treatment or death due to any cause, whichever came first.; OS: time from the systemic treatment onset to death

Trial Locations

Locations (3)

Institut Gustave Roussy, Comprehensive Cancer Center; 🇫🇷 Villejuif, France

Institut Bergonié, Comprehensive Cancer Center; 🇫🇷 Bordeaux, France

Centre Léon Bérard, Comprehensive Cancer Center; 🇫🇷 Lyon, France